Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Doxorubicin-enriched, ALDHbr mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1

Figure 5

The effect of different in vitro treatments on 4T1 ALDH br cells was assessed using flow cytometry. (A) 4T1 cells stained with the aldefluor substrate were imaged using phase-contrast (left) and fluorescence microscopy (right) (100 × objective magnifications). (B) An aldefluor assay of ALDHbr in 4T1 cells treated with either doxorubicin (1.0 μg/ml, middle), HSV1-hGM-CSF (MOI=0.3, right), or media alone (Mock) (left). The upper images in each column are the DEAB-treated negative control, and the lower pictures are the corresponding experimental sample. (C) The ALDHbr cell frequency in the presence of doxorubicin or HSV1-hGM-CSF was compared with the control. The data represent the mean ± SEM of three independent experiments. ***, p<0.001 for a significant difference between the doxorubicin-treated group and the other two groups. Abbreviations: DOX, doxorubicin; OV, HSV1-hGM-CSF.

Back to article page